Abstract
At the pharmaccess leaders forum organised by nextlevel pharam in London in April 2018, Brian Godman, senior resarcher at the Stockholm Karolinska Institute, and Professor affiliated to several universities (including the university of Strathclyde, Glasgow), presented an overview of managed entry agreements (MEAs) for high-cost drugs from the niewpoint of Eurpean reimbursement agencies. He offered coference delegates insights into what pharmaceutical companies can do to conclude successful MEAs. Following the meering, he spoke to Marie-France Courriol for PPR.
| Original language | English |
|---|---|
| Number of pages | 5 |
| Journal | IMS Pharma Pricing & Reimbursement |
| Publication status | Published - 1 Jul 2018 |
Keywords
- managed entry agreements
- pharmacoeconomics
- pharmaceutical companies
- healthcare costs
Fingerprint
Dive into the research topics of 'Managed entry agreements: lessons from European payers'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver